Multiple Myeloma Treatment Drug Submitted to FDA

Janssen ( a Johnson and Johnson Company) Submits Application to U.S. FDA Seeking Approval of New DARZALEX® (daratumumab) Subcutaneous Formulation, Innovative Treatment for Multiple Myeloma RARITAN, N.J., July 12, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration